 

Active ingredient: Betamethasone Acetate; Betamethasone Sodium Phosphate 

 

Form/Route: Injectable Suspension/Injection 

 

Recommended studies: 1 study 

 

Type of study: Fasting 

Design: Single-dose, two-way crossover in-vivo 

Strength: 3 mg/mL; Eq 3 mg Base/mL 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comments: 

 

 

Analytes to measure (in appropriate biological fluid): Betamethasone, Betamethasone 
Acetate, and Betamethasone Phosphate in plasma. 

 

Bioequivalence based on (90% CI): Betamethasone 

 

Please submit data for the pro-drugs (Betamethasone Acetate and Betamethasone Phosphate) as 
supportive evidence of comparable therapeutic outcome. For the pro-drugs, the following data 
should be submitted: individual and mean concentrations, individual and mean pharmacokinetic 
parameters, and geometric means and ratios of means for AUC and Cmax. 

 

Waiver request of in-vivo testing: Not Applicable 

 

Dissolution test method and sampling times: 

 

Please note that Dissolution Method Database is available to the public at the OGD website at 
http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 


